Aarti Drugs Limited (IN:AARTIDRUGS)
:AARTIDRUGS
Want to see IN:AARTIDRUGS full AI Analyst Report?
AARTIDRUGS Stock Chart & Stats
₹404.80
-₹2.25(-0.50%)
At close: 4:00 PM EST
₹404.80
-₹2.25(-0.50%)
Day’s Range― - ―
52-Week Range₹318.60 - ₹574.95
Previous CloseN/A
Volume68.36K
Average Volume (3M)11.99K
Market Cap
₹35.55B
Enterprise Value₹41.27B
Total Cash (Recent Filing)₹245.40M
Total Debt (Recent Filing)₹5.73B
Price to Earnings (P/E)15.0
Beta0.96
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)21.80
Shares Outstanding91,270,000
10 Day Avg. Volume14,342
30 Day Avg. Volume11,994
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)1.88
Price to Sales (P/S)1.14
P/FCF Ratio59.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.7
Revenue Forecast (FY)₹29.50B
Bulls Say, Bears Say
Bulls Say
Improving Balance Sheet And LeverageLower leverage and a strengthening capital base improve financial flexibility, reduce refinancing and interest-rate risk, and support sustained investment in capacity or compliance. A solid balance sheet enables resilience through cycles and funds strategic initiatives without overreliance on external debt.
Diversified API And Specialty-chemicals PortfolioA multi-product, multi-market model spreads demand risk and supports stable revenue streams. Exposure to both pharmaceutical APIs and higher-value specialty chemicals gives pricing and margin diversification, aiding long-term stability as clients seek trusted manufacturing partners and regulatory-compliant suppliers.
Stable Operating MarginsConsistent operating margins indicate durable manufacturing efficiency and cost controls. Even with net-margin pressure, steady core margins suggest the company can maintain competitiveness, cover fixed costs, and generate operating cash to support incremental capex and quality upgrades over the medium term.
Bears Say
Net Margin CompressionSubstantial decline in net margin reduces retained earnings and lowers return on invested capital, constraining the company's ability to self-finance growth or absorb cost shocks. Persistent margin erosion can signal pricing pressure or higher input/regulatory costs that weaken long-term profitability.
Stagnant Top-line GrowthFlat revenues limit scale economies and make margin expansion difficult without material product-mix improvement or new market wins. A lack of consistent organic growth increases dependence on margin recovery or acquisitions to drive earnings, raising execution risk over the medium term.
Volatile And Weak Free Cash FlowInconsistent free cash generation and low cash conversion constrain the firm's ability to fund capex, pay down debt, or return capital. Persistent working-capital drag or investment needs raise funding uncertainty, increasing reliance on external financing and reducing resilience to industry slowdowns.
Aarti Drugs Limited News
AARTIDRUGS FAQ
What was Aarti Drugs Limited’s price range in the past 12 months?
Aarti Drugs Limited lowest stock price was ₹318.60 and its highest was ₹574.95 in the past 12 months.
What is Aarti Drugs Limited’s market cap?
Aarti Drugs Limited’s market cap is ₹35.55B.
When is Aarti Drugs Limited’s upcoming earnings report date?
Aarti Drugs Limited’s upcoming earnings report date is Jul 23, 2026 which is in 60 days.
How were Aarti Drugs Limited’s earnings last quarter?
Aarti Drugs Limited released its earnings results on May 15, 2026. The company reported ₹5 earnings per share for the quarter, the consensus estimate of ₹5 by ₹0.
Is Aarti Drugs Limited overvalued?
According to Wall Street analysts Aarti Drugs Limited’s price is currently Overvalued.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.24%. See more information on Aarti Drugs Limited dividends here
What is Aarti Drugs Limited’s EPS estimate?
Aarti Drugs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Drugs Limited have?
Aarti Drugs Limited has 91,270,000 shares outstanding.
What happened to Aarti Drugs Limited’s price movement after its last earnings report?
Aarti Drugs Limited reported an EPS of ₹5 in its last earnings report, expectations of ₹5. Following the earnings report the stock price went up 1.35%.
Which hedge fund is a major shareholder of Aarti Drugs Limited?
Currently, no hedge funds are holding shares in IN:AARTIDRUGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol C, bisphenol C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―